...
首页> 外文期刊>Journal of International Medical Research >Analysis of drug resistance and mutation profiles in Mycobacterium tuberculosis isolates in a surveillance site in Beijing, China
【24h】

Analysis of drug resistance and mutation profiles in Mycobacterium tuberculosis isolates in a surveillance site in Beijing, China

机译:中国北京监测现场中<浅析结核病患者抗药性和突变曲线分析

获取原文
           

摘要

Objective This study analyzed drug resistance and mutations profiles in Mycobacterium tuberculosis isolates in a surveillance site in Huairou District, Beijing, China. Methods The proportion method was used to assess drug resistance profiles for four first-line and seven second-line anti-tuberculosis (TB) drugs. Molecular line probe assays were used for the rapid detection of resistance to rifampicin (RIF) and isoniazid (INH). Results Among 235 strains of M. tuberculosis , 79 (33.6%) isolates were resistant to one or more drugs. The isolates included 18 monoresistant (7.7%), 19 polyresistant (8.1%), 28 RIF-resistant (11.9%), 24 multidrug-resistant (MDR) (10.2%), 7 pre-extensively drug-resistant (XDR, 3.0%), and 2 XDR strains (0.9%). A higher rate of MDR-TB was detected among previously treated patients than among patients with newly diagnosed TB (34.5% vs. 6.8%). The majority (62.5%) of RIF-resistant isolates exhibited a mutation at S531L in the DNA-dependent RNA polymerase gene. Meanwhile, 62.9% of INH-resistant isolates carried a mutation at S315T1 in the katG gene. Conclusion Our results confirmed the high rate of drug-resistant TB, especially MDR-TB, in Huairou District, Beijing, China. Therefore, detailed drug testing is crucial in the evaluation of MDR-TB treatment.
机译:目的本研究分析了中国北京海欧区监测现场的分枝杆菌分离株中的耐药性和突变曲线。方法采用比例法评估四条一线和七二线抗结核(TB)药物的耐药性曲线。分子线探针测定用于快速检测对利福平(RIF)和异烟肼(INH)的抗性。结果235株肺结核菌株,79(33.6%)分离株对一种或多种药物耐药。该分离株包括18个单抗体(7.7%),19个多种晶体(8.1%),28只离防(11.9%),24个多药(MDR)(10.2%),7种预抗药性(XDR,3.0%) )和2个XDR菌株(0.9%)。在先前治疗的患者中检测到较高速率的MDR-TB,而不是新诊断的TB患者(34.5%vs.6.8%)。大多数(62.5%)的离子抗性分离物在DNA依赖性RNA聚合酶基因中表现出S531L的突变。同时,62.9%的Inh抗性分离物在KATG基因中在S315T1中进行突变。结论我们的结果证实了中国北京怀皇区的耐药TB,特别是MDR-TB的高速率。因此,详细的药物测试对于评估MDR-TB治疗至关重要。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号